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Defining regions of genomic imbalance can identify genes involved in tumour development. Conventional cytogenetics has identified
several nonrandom copy number alterations (CNA) in uveal melanomas (UVM), which include monosomy 3, chromosome 6
abnormalities and gain of 8q. To gain further insight into the CNAs and define the regions involved more precisely we analysed 18
primary UVMs using 1Mb BAC microarray comparative genomic hybridisation (CGH). Our analysis showed that the most common
genomic imbalances were 8q gain (78%), 6p gain (67%) and monosomy 3 (56%). Two distinct CGH profiles could be delineated on
the basis of the chromosome 3 status. The most common genetic changes in monosomy 3 tumours, in our study, were gain of
8q11.21–q24.3, 6p25.1–p21.2, 21q21.2–q21.3 and 21q22.13–q22.3 and loss of 1p36.33–p34.3, 1p31.1–p21.2, 6q16.2–q25.3 and
8p23.3–p11.23. In contrast, disomy 3 tumours showed recurrent gains of only 6p25.3–p22.3 and 8q23.2–q24.3. Our approach
allowed definition of the smallest overlapping regions of imbalance, which may be important in the development of UVM.
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Uveal melanomas (UVM) are the most common primary
intraocular malignant tumours (Stang et al, 2005). Despite
successful treatment of the primary tumour approximately 50%
of patients develop metastatic disease, which is usually unrespon-
sive to chemotherapy and invariably fatal (Bergman et al, 2003).
Tumours most commonly arise in the choroids with less than 10%
developing in the iris and ciliary body. UVMs are classified as
spindle, epithelioid, or mixed according to their histological
appearance (McLean et al, 2004).
Cytogenetic analyses and allelic imbalance studies have identi-
fied a number of recurrent chromosomal aberrations in UVM,
including loss of chromosome 3, and copy number alterations
(CNA) on chromosomes 6 and 8 (Tschentscher et al, 2000; Aalto
et al, 2001; Naus et al, 2001).
In this study we have, for the first time sought to further refine
the regions of chromosomal imbalance in UVM by analysing
tumours using BAC microarray CGH. The resolution of arrays in
identifying regions of chromosome imbalance is dependent upon
the number and distribution of the clones. The arrays used in this
study were based on a previously reported BAC clone set (Fiegler
et al, 2003) and we validated the detection of CNAs in a series of
sex mismatch experiments through which incorrectly annotated
clones were identified and excluded from subsequent analyses. The
median coverage across the genome for the 3421 BACs included
on the array was one clone every 1Mb (range 500Kb–4.5Mb,
excluding BACs spanning centromeres). Detection of copy number
changes is influenced by factors including tumour heterogeneity
and contamination with infiltrating lymphocytes. In this study,
we restricted our analysis to tumours that have been verified to
contain less than 10% normal cell contamination. This approach
has allowed for the definition of chromosomal regions that
represent the smallest overlapping regions of imbalance (SORI),
which are likely to harbour oncogenes or tumour suppressor
genes.
MATERIALS AND METHODS
Patient samples
The tumour samples used in this study (Table 1) were obtained
from different patients attending the Liverpool Ocular Oncology
Centre between 1994 and 1997. All tumours were primary lesions
and the diagnosis of UVM was histologically confirmed in all cases.
In the nine patients alive on the 15 August 2005, the follow-up had
a median of 6.97 years, exceeding 1 and 5 years in 15 patients and
10 patients, respectively. Samples were obtained with informed
consent and Local Ethical Review Board approval in accordance
with the tenets of the Declaration of Helsinki.
Array CGH
DNA was extracted from tumours using the QIAamp DNA Micro
Kit (Qiagen, UK) and the DNA concentration was determined
using the RediPlate 96 PicoGreen dsDNA Quantitation Kit
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s(Invitrogen, UK). Both procedures were performed following
manufacturers instructions. The genomic DNA arrays used in
these experiments were obtained from the Cancer Research UK
DNA Microarray Facility and consist of 3421 BAC and PAC clones,
which provide an average genomic resolution of 1Mb. Reference
DNA (Promega, UK) and test DNA were labelled separately with
Cy3 and Cy5 dyes (Amersham, UK) using the BioPrime Labelling
Kit (Invitrogen, UK), following manufacturers instructions and as
described previously (Douglas et al, 2004).
Test and reference DNAs (50ml each) were combined and
precipitated together with 100mg of human Cot1 DNA (1mgml
 1;
Invitrogen, UK) and 50ml yeast tRNA (5mgml; Invitrogen, UK).
The DNA pellets were resuspended in 10ml of sterile water prior to
being mixed with 10ml of microarray hybridisation solution
(Amersham, UK) and 20ml of deionised formamide (Sigma, UK).
The reconstituted probes were then incubated at 721C for 15min
followed by 30min at 371C. The probes were hybridised to BAC
arrays and incubated for 48–72h at 371C in a humidified chamber.
Table 1 Clinico-pathological characteristics of patients analysed
Tumour ID Gender
Age at diagnosis
(years) Tumour size (mm) Cell type
Metastatic death
from UVM
Chromosome 3
status
15 Male 49 18.0 Mixed + Monosomy
18 Male 72 18.5 Mixed + Monosomy
24 Male 73 17.5 Mixed + Monosomy
33 Male 50 12.8 Mixed   Disomy
40 Male 86 18.8 Mixed + Monosomy
41 Male 29 11.8 Mixed   Disomy
43 Male 67 18.4 Mixed + Monosomy
44 Male 72 17.9 Mixed  
a Monosomy
53 Male 42 20.9 Spindle cell   Monosomy
55 Male 67 14.2 Spindle cell + Disomy
59 Male 57 15.8 Mixed   Disomy
64 Female 42 16.2 Mixed   Monosomy
67 Female 65 19.7 Mixed   Monosomy
69 Female 51 13.6 Mixed   Disomy
75 Male 54 22.2 Mixed   Disomy
76 Male 57 18.4 Mixed + Monosomy
79 Female 81 14.2 Spindle cell  
b Disomy
81 Male 52 12.0 Mixed   Disomy
aMortality from bronchial carcinoma.
bMortality from noncancer related disease.
Table 2 Overview of genetic changes
Tumour sample Loss Gain
15 3p26.3–q27.3, 8p23.3–p11.1 8q11.1–q24.23
18 3p26.3–q27.3, 6q11.1–q25.3, 8p23.3–p11.23 2p24.3–p13.2, 5p15.32–p13.1, 5q11.2–q12.3,
5q13.2–q35.3, 6p25.3–p11.1, 8q11.1–q24.3, 10q22.1–q22.3,
10q23.31–q24.31, 10q26.13–q26.3
24 3p26.3–q27.3, 6q11.1–q25.3, 8p23.3–p11.1 2p25.3–q37.3, 6p25.3–p12.1, 7p22.3–q36.3, 8q11.1–q24.3,
17p13.3–q24.3, 21q11.2–q22.3
33 7p22.3–p12.2, 8p23.3–p11.23 3p12.3–3p11.2
40 1p36.33–p34.3, 1p31.1–q21.1, 3p26.3–q27.3, 6q16.1–q25.3 8q11.1–q24.3, 21q21.2–q21.3
41 10p15.3–p12.33 6p25.3–p22.3, 8q12.2–q24.3, 17q23.2–q24.1
43 1p36.33–p34.3, 3p26.3–q27.3, 6q12.2–q25.3, 4q28.3–q31.3, 6p25.2–p12.1, 7p22.1–q36.3, 8q11.2–q24.3
8p23.3–p11.21, 10p15.3–q26.3, 11q12.3–q13.1, 16p13.12–p12.2,
19p13.3–q13.43, 22q11.1–q13.31
44 3p26.3–q27.3, 6q16.2–q25.3, 8p23.3–p11.1 6p25.3–p21.2, 8q11.1–q24.3
53 1p36.33–q21.2, 3p26.3–q27.3, 9q21.2–q31.3, 4p16.1–p15.1, 4q22.3–q28.1, 6p25.2–q25.3, 7p22.1–q36.3
15q11.2–q26.3 8p23.3–q24.3, 9q33.1–q34.3, 13q12.11–q33.3,
18q22.2–q22.3, 19q13.2–q13.41, 19q13.2–q13.41, 20p12.3–q13.33,
21q21.1–q22.3, 22q11.21–q13.33
55 6p25.3–p12.1, 8q21.13–q24.3
59 6q11.1–q25.3 6p25.3–p12.1, 8q13.3–q24.3, 9p13.2–q34.3
64 1p36.33–p11.2, 3p26.3–q27.3, 4q13.3–q35.2, 15q11.2–q26.3 1q21.1–q42.3, 4p16.2–p13.1, 8p23.3–q24.3, 21q11.2–q22.3
67 1p36.33–q42.3, 3p26.3–q27.3, 6p25.3–q25.3, 13q12.11–q33.3,
14q11.2–q32.33, 15q11.1–q26.3, 16p13.3–q24.3, 17p11.2–q25.3,
18p11.32–q22.3, 22q11.1–q13.33
7p22.3–q36.3, 20p12.3–q13.33, 21q22.13–q22.3
69 6q16.3–q25.3, 8p23.3–p11.1 6p25.3–p12.1, 8q23.2–q24.3
75 1p36.22–p34.2, 5q35.3, 9q34.2–q34.3, 16p13.12–p12.2, 17q21.1–
q21.31, 19p13.2–q13.43, 22q11.21–q13.31
6p25.3–q11.1, 7p21.3–q36.3, 8p23.2–q24.3
76 3p26.3–q27.3, 8p23.3–p11.1 8q11.1–q24.3
79 6p25.3–p11.1
81 6q11.1–q25.3 6p25.3–p12.1, 8q13.3–q24.3, 9p24.3–q21.3
Highly amplified regions in bold.
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sSlides were washed for 15min at 421Ci n2   SSC, 0.1% SDS,
15min at 421C in 50% formamide/2  SSC, 30min at 421Ci n
2  SSC, 0.1% SDS and 15min at room temperature in 0.2  SSC,
before being dried by spinning in a centrifuge for 5min at 150g.
Data collection and analysis
The slides were scanned using an Axon GenePix 4000A confocal
scanner, each fluorescence signal was collected separately and
quantified with the GenePix Pro 3.0 software (Axon Instruments,
USA). Spots were defined by use of the automatic grid feature
of the software and manually adjusted where necessary. The data
was normalised and analysed using Normalise Suite v2.4 (Beheshti
et al, 2003), regions of loss or gain were determined as those that
were 2 s.d. above the mean baseline for each separate sample.
RESULTS AND DISCUSSION
The data presented here are based on the array CGH analysis of 18
UVMs. Figure 1 shows representative CGH profiles for chromo-
some 6, 8 and 21. Table 2 shows the chromosomal changes for all
18 tumours analysed, and Figure 2 shows the frequency of CNAs
detected at the level of each chromosome arm. The overall
frequency of alterations observed in the 18 tumours was higher
than has been previously reported in metaphase CGH studies of
UVM (Ghazvini et al, 1996; Tschentscher et al, 2000; Aalto et al,
2001; Naus et al, 2001). This reflects the greater sensitivity of array
CGH.
Previous reports have stated that the most frequent anomaly in
UVM is loss of an entire copy of chromosome 3 (Sisley et al, 1992;
Wiltshire et al, 1993; White et al, 1998). In our analysis, however,
the most common chromosomal changes identified were 8q gains
(14/18; 78, 95% confidence interval: 52–94%), 6p gains (12/18; 78,
95% confidence interval: 41–87%), and monosomy 3 (10/18; 56,
95% confidence interval: 31–78%). Less common CNAs were loss
of 1p (6/18; 33%), 6q (7/18; 39%) and 8p (8/18; 44%), and gain of
7p (5/18; 28%) and 21q (5/18; 28%).
Inspection of the CGH profiles of monosomy 3 and disomy 3
tumours delineated two tumour types; a division supported by
hierarchical clustering of the CGH data (see Supplementary data)
and published microarray expression data (Tschentscher et al,
2003). In all, 10 tumours had monosomy 3 and eight disomy 3.
Figure 2 shows the frequency of genomic imbalance, at the
chromosome arm level, stratified by chromosome 3 status.
Compared to disomy 3 melanomas, monosomy 3 tumours showed
more frequent loss of chromosomal material from 1p, 6q and 8p in
addition to gain of 7 and 21q. Furthermore, the regions of change
in disomy 3 tumours, in some cases, involved less of the affected
chromosomal arms than monosomy 3 tumours (Table 2). This
probably reflects increase genomic instability in monosomy 3
tumours (Myatt et al, 2000).
Previously published analyses of chromosome 3 in UVM have
shown that partial deletions of monosomy 3 are detectable in
approximately 50% of tumours and have defined two minimum
regions of loss, 3p25.1–p25.2 and 3q24–q26 (Tschentscher et al,
2001; Parrella et al, 2003). All the tumours we analysed with loss
of chromosome 3 material showed loss of the entire chromosome,
thus we were not able to further refine either of these regions of
deletion.
Monosomy 3 has been hypothesised to represent an early event
in tumourigenesis, defining a bificated tumour progression
pathway (Parrella et al, 1999; Hoglund et al, 2004). In our study
there was an inverse relationship between monosomy 3 and gain of
6p (Fishers exact test P¼0.06). It has been proposed that at least
two cytogenetic pathways of clonal evolution exist for UVMs, one
initiated with monosomy 3 and one with gain of 6p (Hoglund et al,
2004).
UVMs characterised by monosomy 3 are associated with a
greater tumour size and a poor prognosis for survival (Prescher
et al, 1996; Sisley et al, 1997; Scholes et al, 2003). Although our
study did not permit survivorship associated with monosomy 3 to
be formally assessed, it is noteworthy that six of the 10 patients
with monosomy 3 tumours developed metastatic disease compared
with only one of the eight patients with disomy 3 tumours (Fishers
exact test P¼0.06). In our study, excluding anomalies of
chromosome 3, the frequency of CNAs were higher, albeit
nonsignificantly, in the tumours with monosomy 3 than in
Loss Gain
Fluorescence ratio
0 0.5 1.0 1.5 2.0
Chromosome 6 (tumour sample 24)
Chromosome 8 (tumour sample 44)
Chromosome 21 (tumour sample 64)
Loss Gain
Fluorescence ratio
0 0.5 1.0 1.5 2.0
Fluorescence ratio
0 0.5 1.0 1.5 2.0
Loss Gain
A
B
C
Figure 1 Examples of array CGH data, (A) 6p gain and 6q loss (tumour
sample 24), (B) 8p loss and 8q gain (tumour sample 44) and (C) gain of 21
(tumour sample 64). The data was normalised and analysed using
Normalise Suite v2.4 (Beheshti et al, 2003), regions of loss (left of the
central line) or gain (right of the central line) were determined as those that
were 2 s.d. (denoted by dashed black or gray lines) from the mean baseline
for each separate sample.
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stumours with disomy 3 (Mann–Whitney test, Po0.10); 7.5 CNAs
(range 2–20) and 3.5 CNAs (range 1–13) respectively. Recent
work on other cancers has shown prognosis is worse when high
rates of chromosome instability are a feature, probably a
consequence of the accumulation of induced genetic alterations
(Nakamura et al, 2003). This might explain the better prognosis
observed for UVM patients with disomy 3 tumours. In our study
tumours with monosomy 3 were larger than those with disomy 3
(Mann–Whitney test, Po0.008; median sizes 18.4mm (range
16.2–20.9mm) and 13.9mm (range 11.8–22.2mm, respectively)
and after adjusting for tumour size there was little support for a
relationship between monosomy 3 status and frequency of CNAs
per se (P¼0.80). Although only a small number of tumours were
analysed in our study this finding invites speculation that
monosomy 3 may be a consequence of clonal selection during
tumour progression.
To identify SORI at each region of CNA, genomic distances
spanning regions of imbalance were determined separately for
monosomy 3 and disomy 3 tumours, at the resolution of individual
BAC clones. The data from tumours in each group were then
compared and the SORI defined for each chromosome. The SORI
involving at least two of the 10 monosomy 3 tumours or two of the
eight disomy 3 tumours are shown in Table 3. The SORI data
described here (Table 3) corroborate the previously identified
regions of imbalance reported to be associated with UVMs
(Aalto et al, 2001; Naus et al, 2001), specifically, 6p (6p25.1–p21.2),
6q (6q16.2–q25.3) and 8p (8p23.3–p11.23). Furthermore, our
SORI data delineates a number of additional minimal regions of
imbalance in monosomy 3 patients, several less than 30Mb, as
detailed in Table 3.
In addition to confirming and refining, at base pair resolution, a
number of previously reported CNAs, the use of high-resolution
array CGH has allowed us to accurately delineate (to within 1Mb)
a number of rarely reported chromosomal regions of abnormality
in UVM. The minimum regions defined are likely to harbour genes
important to the development of UVMs.
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Figure 2 Summary of chromosomal losses and gains in (A) all tumours (n¼18), (B) monosomy 3 (n¼10) and (C) disomy 3 (n¼8) tumours.
Proportion of tumours of each type with gain and loss at the level of the chromosome arm are shown by black and grey bars, respectively.
Microarray comparative genomic hybridisation analysis
S Hughes et al
1194
British Journal of Cancer (2005) 93(10), 1191–1196 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sACKNOWLEDGEMENTS
We are grateful to the patients who participated in this study. The
work was supported by Grants from Cancer Research UK. Simon
Hughes was supported by a grant from the Wellcome Trust. We
are grateful to Janet Shipley for her helpful criticisms and
comments.
Supplemenatry information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc).
REFERENCES
Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S (2001) Concomitant
loss of chromosome 3 and whole arm losses and gains of chromosome 1,
6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis
Sci 42: 313–317
Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA (2003)
Chromosomal localization of DNA amplifications in neuroblastoma
tumors using cDNA microarray comparative genomic hybridization.
Neoplasia 5: 53–62
Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-
Olding B (2003) Uveal melanoma survival in Sweden from 1960–1998.
Invest Ophthalmol Vis Sci 44: 2579–2583
Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W,
Tomlinson IP, Carter NP (2004) Array comparative genomic hybridiza-
tion analysis of colorectal cancer cell lines and primary carcinomas.
Cancer Res 64: 4817–4825
Dunne BM, McNamara M, Clynes M, Shering SG, Larkin AM, Moran E,
Barnes C, Kennedy SM (1998) MDR1 expression is associated
with adverse survival in melanoma of the uveal tract. Hum Pathol 29:
594–598
Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie
D, Gorman P, Tomlinson IP, Carter NP (2003) DNA microarrays for
comparative genomic hybridization based on DOP-PCR amplification of
BAC and PAC clones. Genes Chromosomes Cancer 36: 361–374
Ghazvini S, Char DH, Kroll S, Waldman FM, Pinkel D (1996) Comparative
genomic hybridization analysis of archival formalin-fixed paraffin-
embedded uveal melanomas. Cancer Genet Cytogenet 90: 95–101
Table 3 Smallest overlapping regions of imbalance found by array CGH for patients displaying (a) monosomy 3 (n¼10) and (b) disomy 3 (n¼8), in
addition, to the genes either over expressed or under expressed with in these regions
Affected region
Smallest overlapping
region of imbalance
(SORI)
SORI
incidence
Chromosome position
in base pairs Mb size
Approximate
number of genes
Genes reported to be
differentially expressed
in UVM*
Gains Upregulated
(a)
2p25.3–q37.3 2p24.3–p13.2 2/10 (20%) 16036517–68981280 52.9 180
4p16.1–p15.1 4p16.1–p15.1 2/10 (20%) 10782302–34782661 24.0 42
6p25.3–p11.1 6p25.1–p21.2 5/10 (50%) 5060091–37828169 32.7 380 HMGIY, HLA-DPA1
7p22.3–q36.3 7p22.1–q36.3 4/10 (40%) 7725571–158345327 150.6 862 EGFR, HOXA11 and 13,
HGF, CDK6, EPO, BRAF
8p23.3–q24.3 8q11.21–q24.3 8/10 (80%) 49397958–146062919 96.7 367 RRM2B, TSPYL5, CGI-12,
PRKDC, TAF2
20p12.3–q13.33 20p12.3–q13.33 2/10 (20%) 6285715–63648414 57.3 414 JAG1
21q11.2–q22.3 21q21.2–q21.3 4/10 (40%) 24509084–28625616 4.1 11 SOD1
21q22.13–q22.3 4/10 (40%) 34482486–46798642 12.3 135 S100B
Losses Downregulated
1p36.33–q21.3 1p36.33–p34.3 5/10 (50%) 1059869–36259335 35.2 399 PTP4A2, VAMP3,
1p31.1–p21.2 4/10 (40%) 73223190–94336358 29.1 112 IL12RB2, PDE4B, PLXNB1,
3p26.3–q27.3 3p26.3–q27.3 10/10 (100%) 186817–198819498 198.6 944 CHL1, H1FX, fls485,
ROBO1, SETMAR, IL1RAP,
NR1D2, RAF1, MBD4,
CTNNB1, eIF2a, RPL24,
GC20, RPL15, PIK3R4,
FXR1, TKT, RAP2B, WIG1
6q11.1–q25.3 6q16.2–q25.3 6/10 (60%) 96260894–170637357 74.3 291
8p23.3–p11.1 8p23.3–p11.23 6/10 (60%) 477644–35173110 34.8 160 ATIP1
15q11.1–q26.3 15q11.2–q26.3 3/10 (30%) 20401349–99832748 79.4 354 SMAD3
16p13.12–16p12.2 16p13.12–16p12.2 2/10 (20%) 13892248–21963275 8.0 57 COX6A2, MVP
22q11.1–22q13.31 22q11.1–22q13.31 2/10 (20%) 15615802–44352473 28.8 352 TIMP3, PDGFB
(b)
Gains Unregulated
6p25.3–p11.1 6p25.3–p22.3 7/8 (87.5%) 90997–19131250 18.2 81 HMGIY, HLA-DPA1
8q12.2–q24.3 8q23.2–q24.3 6/8 (75%) 108867491–146062919 37.2 164 TAF2
9p13.2–9q21.33 9p13.2–9q21.33 2/8 (25%) 28840514–79219038 50.4 127
Losses Downregulated
6q14.1–6q25.3 6q16.3–q25.3 3/8 (37.5%) 97763086–170637357 72.9 291
8p23.3–p11.23 8p23.3–p11.23 2/8 (25%) 477644–35173110 34.8 160 ATIP1
*Data extracted from Dunne et al, 1998; Hendrix et al, 1998; Hurks et al, 2000; Onken et al, 2004; Radosevich et al, 2004; Tschentscher et al, 2003; van der Velden et al, 2003;
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